Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LPL | P06858 | 9/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211744 | 0.89 | KDM4E (0.52) | ALDH1A1ROCK1KDM4ESMN1; SMN2LPL | |
| SCHEMBL21644162 | 0.88 | KDM4E (0.55) | ALDH1A1ROCK1KDM4ESMN1; SMN2LPL | |
| SCHEMBL17427861 | 0.82 | KDM4E (0.54) | ALDH1A1KDM4E | |
| SCHEMBL16023943 | 0.79 | SCN9A (0.46) | ALDH1A1ROCK1KDM4ESMN1; SMN2LPL | |
| SCHEMBL18579955 | 0.79 | ROCK1 (0.53) | ALDH1A1ROCK1KDM4ESMN1; SMN2LPL | |
| SCHEMBL428922 | 0.79 | CYP2A13 (0.50) | ALDH1A1ROCK1KDM4ESMN1; SMN2LPL | |
| SCHEMBL27160039 | 0.79 | MGLL (0.39) | ROCK1SMN1; SMN2LPLLIPGCYP2A13 | |
| SCHEMBL29914778 | 0.79 | MGLL (0.39) | ROCK1SMN1; SMN2LPLLIPGCYP2A13 | |
| SCHEMBL18580183 | 0.78 | ROCK1 (0.45) | ALDH1A1ROCK1KDM4ESMN1; SMN2 | |
| SCHEMBL15573562 | 0.78 | LPL (0.49) | ROCK1LPLLIPGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | INCYTE CORP (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | JAK1, TYK2, JAK2 | ALDH1A1 1336/4885ROCK1 77/4885KDM4E 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.